You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Programmed cell death protein 1 antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

Enrolling by invitation
  • Hepatocellular Carcinoma Non-resectable
  • +3 more
  • lenvatinib + sindilimab/carrelizumab
  • TACE
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 23, 2022

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Bladder Cancer Trial in Korea, Republic of, Poland, United States (PF-07225570, sasanlimab)

Recruiting
  • Bladder Cancer
  • New York, New York
  • +5 more
Jun 28, 2022

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

Recurrent/ Advanced Stage Endometrial Cancer Patients Trial in Guangzhou (Niraparib in Combination With Anti-PD1 Antibody)

Recruiting
  • Recurrent/ Advanced Stage Endometrial Cancer Patients
  • Niraparib in Combination With Anti-PD1 Antibody
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Centre
Aug 20, 2021

Hepatocellular Carcinoma Trial in Shanghai (Toripalimab, Sorafenib)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Zhongshan Hospital
Jun 14, 2021

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (combined therapy using oxaliplatin and gemcitabine chemo, Lenvatinib and PD1

Active, not recruiting
  • Cholangiocarcinoma, Intrahepatic
  • combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Jul 5, 2021

EBV Infection Trial in Beijing (PD1 antibody, lenalidomide)

Recruiting
  • EBV Infection
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Jan 4, 2022

EBV Infection Trial in Suzhou (PD-1 mAb)

Recruiting
  • EBV Infection
  • PD-1 monoclonal antibody
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 1, 2021

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center, Sun Yat-sen University
Aug 3, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

Not yet recruiting
  • Acute Lymphoblastic Leukemia in Pediatric
  • flow cytometric immunophynotyping
  • Sohag, Egypt
    Sohag University Hospital
Jun 19, 2022

Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

Recruiting
  • Head and Neck Cancer
  • Strasbourg, France
    Institut de cancérologie Strasbourg Europe
Apr 14, 2022

Advanced Solid Tumors Trial in Australia (HLX20)

Completed
  • Advanced Solid Tumors
  • Darlinghurst, New South Wales, Australia
  • +5 more
Jun 1, 2022

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

Recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Nivolumab
  • Pembrolizumab
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022

PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Recruiting
  • Non-small Cell Lung Cancer
  • Monza, Italy
    ASST-Monza Ospedale San Gerardo
Jun 9, 2022

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Peking, China
    Peking Union Medical College Hospital
Nov 16, 2023

Carcinoma, Hepatocellular, Liver Tumors, Sintilimab Trial in Guangzhou (Hepatic arterial infusion chemo, Lenvatinib, Sintilimab)

Unknown status
  • Carcinoma, Hepatocellular
  • +3 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Second Affiliated Hospital of Guangzhou Medical University
Dec 20, 2020